Liftstream is an executive search recruitment company in the life sciences sector
Third Rock Ventures shows promise with early stage investment strategy
Authored by Karl Simpson – April 2013
Audentes Therapeutics raises $30 in series A financing
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged 5AM Ventures, Audentes Therapeutics, Bluebird bio, Chiesi, Gene therapy, Glybera, Jonathan Silverstein, Kush Parmar, Matthew R. Patterson, OrbiMed Advisors, Orphan drugs, Pompe Disease, rare diseases, series A funding, Thomas J. Schuetz, Thomas Woiwode, uniQure, venture capital, Versant Ventures, x-linked myotubular myopathy, XLMTM
Leave a comment
Bluebird IPO shows gene therapy on upward trajectory
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Agios Pharmaceuticals, Bluebird bio, Cardio3 Bioscience, celgene, childhood cerebral ALD, Epizyme, europe, Gene therapy, haematology, IPO, IPO Window, Lenti D, Nick Leschly, oncology, Onconova Therapeutics, Prosensa, public offering, shares, Shire, Shire HGT, Third Rock Ventures, USA
Leave a comment
GenSight investment profits from gene therapy buzz
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged Abingworth LLP, Bernard Gilly, Bluebird bio, Boehringer Ingelheim, celgene, Gene therapy, GenSight Biologics, Glybera, Index Ventures, Jen Bennet, Leber’s Hereditary Optic Neuropathy, Novartis Venture Funds, Paris, Professor Jose-Alain Sahel, Transgene, uniQure, University of Pennsylvania, Vision Institute
Leave a comment
13 Life Science Leaders to watch in 2013
Authored by Liftstream
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged Abbott, AbbVie, Amgen, Angus Russell, AstraZeneca, Bluebird bio, Cancer Vaccine, CEO, Cystic Fibrosis, Dalvir Gill, David Mott, Director General EFPIA, EFPIA, EMEA, Erbitux, FDA, Flemming Ornskov, Foundation Medicine, FoundationOne, Gattex, Gene therapy, Gilead Sciences, Glybera, HCV, Hepatitis, Humira, INSPIRE, Jeff Leiden, Jeremy Levin, John Martin, Kalydeco, Karl-Ludwig Kley, Lotus Tissue Repair, Merck KGaA, Michael Pellini, Natpara, New Enterprise Associates, NP Pharmaceuticals, oncology, Orphan drugs, Pascal Soriot, rare diseases, Richard Bergstrom, Richard Gonzalez, Shire, Shire Speciality pharma, Sofosbuvir, Stimuvax, Takeda, Teva, TransCelerate, Ultragenyx, uniQure, Vertex Pharmaceuticals, Vyvanse
Leave a comment
The Resurgence of Gene Therapy
Authored by James Sheppard
Posted in General, Orphan Drugs and Rare Diseases
Tagged ADA-SCID, Alzehimers, Ashanti DeSilva, Bluebird bio, cancer, Cedars-Sinai Heart Institute in Los Angeles, Gene therapy, genetics, GenVec, Genzyme, GlaxoSmithKline, Glybera, GSK, Jesse Gelsinger, LCA, Lebers Congential Amaurosis, Moorfield Eye Hospital, Novartis, Pfizer, Rare Disease, Tacere Therapeutics, uniQure, University College London
Leave a comment
Bluebird bio sings to tune of $9.3m as gene therapy shows promise
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases
Tagged Alnylan Pharmaceuticals, ARCH Ventures, beta-thalassemia/sickle cell anemia, Biogen IDEC, Bluebird bio, CCALD, celgene, childhood cerebral adrenoleukodystrophy, Deerfield partners, Genzyme, LentGlobin, Mark Levin, Nick Leschly, Orphan Drug, rare diseases, Shire, Third Rock Ventures, venture capital
Leave a comment